Results 1 to 10 of about 313,244 (194)

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM [PDF]

open access: yesMediators of Inflammation, 2015
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in human epithelioma but with relatively low expression in normal epithelial tissues.
Minghua Lv   +9 more
doaj   +7 more sources

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression [PDF]

open access: yesBiomedicines, 2019
For the recombinant expression of toxin-based drugs, a crucial step lies not only in the choice of the production host(s) but also in the accurate design of the protein chimera.
Stefania Zuppone, Riccardo Vago
exaly   +5 more sources

DT389-YP7, A Recombinant Immunotoxin Against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An in Vitro Study [PDF]

open access: yesToxins, 2021
Hepatocellular carcinoma (HCC) is one of the high-metastatic types of cancer, and metastasis occurs in one-third of patients with HCC. To maintain the effectiveness of drug compounds on cancer cells and minimize their side effects on normal cells, it is ...
Mohammad Heiat   +2 more
exaly   +4 more sources

Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin [PDF]

open access: yesBMC Biotechnology, 2020
Background Immunotoxin is a hybrid protein consisting of a toxin moiety that is linked to a targeting moiety for the purpose of specific elimination of target cells.
William F. Jiemy   +4 more
doaj   +2 more sources

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma [PDF]

open access: yesBiology, 2022
Over 90% of head and neck squamous cell carcinoma (HNSCC) overexpresses the epidermal growth factor receptor (EGFR). However, the EGFR-targeted monotherapy response rate only achieves 10–30% in HNSCC.
Guiqin Xie   +4 more
doaj   +2 more sources

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma [PDF]

open access: yesScientific Reports, 2023
The innate immune stimulator of interferon genes (STING) pathway is known to activate type I interferons (IFN-I) and participate in generating antitumor immunity.
Guiqin Xie   +7 more
doaj   +2 more sources

Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells [PDF]

open access: yesPeerJ, 2021
Background KRAS oncogenes harboring codon G12 and G13 substitutions are considered gatekeeper mutations which drive oncogenesis in many cancers.
Michelle Yee Mun Teo   +6 more
doaj   +3 more sources

Targeting of specific neuronal types in the non-human primate brain by using a murine CD25-specific recombinant immunotoxin [PDF]

open access: yesScientific Reports
Immunotoxin (ITX)-mediated cell targeting enables selective elimination of neuronal types of interest from a complex neural network. In this technology, human interleukin-2 receptor α-subunit or CD25 (hCD25) is expressed in specific cell types in ...
Tomoko Kobayashi   +9 more
doaj   +2 more sources

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture [PDF]

open access: yesBMC Research Notes, 2019
Objective Recombinant immunotoxins (RITs) are antibody-toxin fusion proteins that can selectively eliminate populations of cells expressing specific surface receptors. They are in evaluation as therapeutic agents for cancer.
Yuyi Zhu, John E. Weldon
doaj   +2 more sources

A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A [PDF]

open access: yesFrontiers in Veterinary Science
Canine lymphoma is one of the most common and aggressive hematopoietic tumors in dogs. Despite recent advances in veterinary cancer treatments, the lack of specificity, side effects, and resistance to conventional chemotherapies has opened an urgent need
Ana S. André   +28 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy